Acquisition by Ives Jeffrey L. of 44961 shares of Cara Therapeutic at 3.09 subject to Rule 16b-3
| CARA Stock | USD 5.12 0.08 1.59% |
About 55% of Cara Therapeutic's investors are presently thinking to get in. The analysis of overall sentiment of trading Cara Therapeutic stock suggests that some investors are interested at this time. The current market sentiment, together with Cara Therapeutic's historical and current headlines, can help investors time the market. In addition, many technical investors use Cara Therapeutic stock news signals to limit their universe of possible portfolio assets.
Cara |
Filed transaction by Cara Therapeutic Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cara Therapeutic Fundamental Analysis
We analyze Cara Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cara Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cara Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Cara Therapeutic is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Cara Therapeutic Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cara Therapeutic stock to make a market-neutral strategy. Peer analysis of Cara Therapeutic could also be used in its relative valuation, which is a method of valuing Cara Therapeutic by comparing valuation metrics with similar companies.
Peers
Cara Therapeutic Related Equities
| CRBP | Corbus Pharmaceuticals | 0.26 |
| ||
| XXII | 22nd Century | 7.99 |
|
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |